摘要
目的探讨血清IL-35在炎症性肠病(IBD)患者血清中的表达及意义。方法采用双抗夹心酶联免疫吸附法(ELISA)检测101例IBD患者及69例健康对照组的血清IL-35和TNF-α的浓度,采用相关分析法分析实验组血清IL-35水平与炎症指标的相关性。结果溃疡性结肠炎(UC)、克罗恩病(CD)和健康对照组的血清IL-35浓度分别为(41.34±16.06)、(48.85±19.14)和(78.17±17.96)pg/ml,差异有统计学意义(P<0.05);UC和CD患者血清IL-35浓度均随着疾病活动度的增加而降低,各等级间差异有统计学意义(P<0.05)。IBD组血清IL-35浓度与血清TNF-α浓度呈负相关(γ=–0.321,P=0.001)。结论 IBD患者血清IL-35水平明显低于正常人,并且与疾病活动度、TNF-α相关。
Objective To investigate the expression level and clinical value of serum IL-35 from inflammatory bowel disease（IBD） patients. Methods ELISA was applied to detect the serum IL-35 and TNF-α levels in 101 cases of IBD patients and 69 cases of healthy individuals. Results The concentration of IL-35 in serum was（41.34 ± 16.06）pg/ml in ulcerative colitis（UC）,（48.85 ± 19.14）pg/ml in Crohn＇s disease（CD）,（78.17 ± 17.96）pg/ml in control group, respectively and the difference was statistically significant（P〈0.05） as compared to control group. Serum IL-35 levles from both UC and CD patients were reduced with the increase of disease activity, the difference was statistically significant between ranks（P〈0.05）. In addition, serum IL-35 and TNF-α concentration were negatively correlated in IBD group（γ = –0.321, P = 0.001）. Conclusion Serum IL-35 levels were significantly decreased in IBD patients as compared to control group, and is expected to be a promising indicator by using to assess IBD disease activity.
出处
《中国医药生物技术》
2016年第2期142-144,共3页
Chinese Medicinal Biotechnology
